Protein and Glycan Mimicry in HIV Vaccine Design

Overview

Journal J Mol Biol

Publisher Elsevier

Specialties Microbiology
Molecular Biology

Date 2019 Apr 28

PMID 31028779

Citations 67

Authors

Gemma E Seabright

Katie J Doores

Dennis R Burton

Max Crispin

Affiliations

Soon will be listed here.

Abstract

Antigenic mimicry is a fundamental tenet of structure-based vaccinology. Vaccine strategies for the human immunodeficiency virus type 1 (HIV-1) focus on the mimicry of its envelope spike (Env) due to its exposed location on the viral membrane and role in mediating infection. However, the virus has evolved to minimize the immunogenicity of conserved epitopes on the envelope spike. This principle is starkly illustrated by the presence of an extensive array of host-derived glycans, which act to shield the underlying protein from antibody recognition. Despite these hurdles, a subset of HIV-infected individuals eventually develop broadly neutralizing antibodies that recognize these virally presented glycans. Effective HIV-1 immunogens are therefore likely to involve some degree of mimicry of both the protein and glycan components of Env. As such, considerable efforts have been made to characterize the structure of the envelope spike and its glycan shield. This review summarizes the recent progress made in this field, with an emphasis on our growing understanding of the factors shaping the glycan shield of Env derived from both virus and soluble immunogens. We argue that recombinant mimics of the envelope spike are currently capable of capturing many features of the native viral glycan shield. Finally, we explore strategies through which the immunogenicity of Env glycans may be enhanced in the development of future immunogens.

Citing Articles

Evaluating the Impact of N-Glycan Sequon Removal in the p27 Peptide on RSV F Protein Immunogenicity and Functionality.

Jacobs L, Leemans A, Stobbelaar K, Fransen A, Cos P, Delputte P Viruses. 2025; 16(12.

PMID: 39772158 PMC: 11680209. DOI: 10.3390/v16121848.

Microbial Polysaccharides as Functional Components of Packaging and Drug Delivery Applications.

Yermagambetova A, Tazhibayeva S, Takhistov P, Tyussyupova B, Tapia-Hernandez J, Musabekov K Polymers (Basel). 2024; 16(20).

PMID: 39458682 PMC: 11511474. DOI: 10.3390/polym16202854.

Beyond glycan barriers: non-cognate ligands and protein mimicry approaches to elicit broadly neutralizing antibodies for HIV-1.

Walimbwa S, Maly P, Raskova Kafkova L, Raska M J Biomed Sci. 2024; 31(1):83.

PMID: 39169357 PMC: 11337606. DOI: 10.1186/s12929-024-01073-y.

mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies.

Xie Z, Lin Y, Steichen J, Ozorowski G, Kratochvil S, Ray R Science. 2024; 384(6697):eadk0582.

PMID: 38753770 PMC: 11488660. DOI: 10.1126/science.adk0582.

Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines.

Moral-Sanchez I, Wee E, Xian Y, Lee W, Allen J, Torrents de la Pena A NPJ Vaccines. 2024; 9(1):74.

PMID: 38582771 PMC: 10998906. DOI: 10.1038/s41541-024-00862-8.

References

Calarese D, Lee H, Huang C, Best M, Astronomo R, Stanfield R . Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci U S A. 2005; 102(38):13372-7. PMC: 1224641. DOI: 10.1073/pnas.0505763102. View

Mascola J, Lewis M, Stiegler G, Harris D, Vancott T, Hayes D . Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol. 1999; 73(5):4009-18. PMC: 104180. DOI: 10.1128/JVI.73.5.4009-4018.1999. View

Pritchard L, Harvey D, Bonomelli C, Crispin M, Doores K . Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope. J Virol. 2015; 89(17):8932-44. PMC: 4524065. DOI: 10.1128/JVI.01190-15. View

Sok D, Le K, Vadnais M, Saye-Francisco K, Jardine J, Torres J . Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows. Nature. 2017; 548(7665):108-111. PMC: 5812458. DOI: 10.1038/nature23301. View

Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N . Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol. 1996; 70(2):1100-8. PMC: 189917. DOI: 10.1128/JVI.70.2.1100-1108.1996. View

Plotkin S . Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J. 2001; 20(1):63-75. DOI: 10.1097/00006454-200101000-00013. View

Hoot S, McGuire A, Cohen K, Strong R, Hangartner L, Klein F . Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog. 2013; 9(1):e1003106. PMC: 3536657. DOI: 10.1371/journal.ppat.1003106. View

Calarese D, Scanlan C, Zwick M, Deechongkit S, Mimura Y, Kunert R . Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science. 2003; 300(5628):2065-71. DOI: 10.1126/science.1083182. View

Medina-Ramirez M, Garces F, Escolano A, Skog P, de Taeye S, Moral-Sanchez I . Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. J Exp Med. 2017; 214(9):2573-2590. PMC: 5584115. DOI: 10.1084/jem.20161160. View

10.

Ringe R, Sanders R, Yasmeen A, Kim H, Lee J, Cupo A . Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci U S A. 2013; 110(45):18256-61. PMC: 3831437. DOI: 10.1073/pnas.1314351110. View

11.

Dacheux L, Moreau A, Ataman-Onal Y, Biron F, Verrier B, Barin F . Evolutionary dynamics of the glycan shield of the human immunodeficiency virus envelope during natural infection and implications for exposure of the 2G12 epitope. J Virol. 2004; 78(22):12625-37. PMC: 525068. DOI: 10.1128/JVI.78.22.12625-12637.2004. View

12.

Stoddart C, Galkina S, Joshi P, Kosikova G, Long B, Maidji E . Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice. Virology. 2014; 462-463:115-25. PMC: 4125441. DOI: 10.1016/j.virol.2014.05.036. View

13.

Doores K, Bonomelli C, Harvey D, Vasiljevic S, Dwek R, Burton D . Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A. 2010; 107(31):13800-5. PMC: 2922250. DOI: 10.1073/pnas.1006498107. View

14.

Go E, Hewawasam G, Liao H, Chen H, Ping L, Anderson J . Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry. J Virol. 2011; 85(16):8270-84. PMC: 3147976. DOI: 10.1128/JVI.05053-11. View

15.

Kong L, He L, de Val N, Vora N, Morris C, Azadnia P . Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability. Nat Commun. 2016; 7:12040. PMC: 4931249. DOI: 10.1038/ncomms12040. View

16.

Leonard C, Spellman M, Riddle L, Harris R, Thomas J, Gregory T . Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem. 1990; 265(18):10373-82. View

17.

Pritchard L, Spencer D, Royle L, Vasiljevic S, Krumm S, Doores K . Glycan Microheterogeneity at the PGT135 Antibody Recognition Site on HIV-1 gp120 Reveals a Molecular Mechanism for Neutralization Resistance. J Virol. 2015; 89(13):6952-9. PMC: 4468474. DOI: 10.1128/JVI.00230-15. View

18.

Falkowska E, Ramos A, Feng Y, Zhou T, Moquin S, Walker L . PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J Virol. 2012; 86(8):4394-403. PMC: 3318667. DOI: 10.1128/JVI.06973-11. View

19.

Jardine J, Julien J, Menis S, Ota T, Kalyuzhniy O, McGuire A . Rational HIV immunogen design to target specific germline B cell receptors. Science. 2013; 340(6133):711-6. PMC: 3689846. DOI: 10.1126/science.1234150. View

20.

Julien J, Lee J, Ozorowski G, Hua Y, Torrents de la Pena A, de Taeye S . Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens. Proc Natl Acad Sci U S A. 2015; 112(38):11947-52. PMC: 4586835. DOI: 10.1073/pnas.1507793112. View